Precision Bio extends cash runway to 2028 on $75M raise; HBV shows cccDNA elimination

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

Key Changes

• high

  Q1 revenue jumped to $10.8M from near-zero a year ago, driven by a $7.5M TG Therapeutics milestone payment (split $5.25M cash, $2.25M stock purchase) and legacy agriculture collaboration revenue.

  MD&A: Revenue Recognition verify on EDGAR →
• high

  PBGENE-HBV delivered first clinical evidence of cccDNA elimination in liver biopsies, the primary mechanism of action, to be presented at EASL Congress 2026—a key efficacy milestone for the lead program.

  MD&A: PBGENE-HBV Clinical Progress verify on EDGAR →
• high

  Cash runway extended from mid-2026 to through 2028 following November 2025 public offering that raised $70M net proceeds; company now projects funding PBGENE-HBV and PBGENE-DMD data milestones through 2028.

  Risk Factors: Cash Runway verify on EDGAR →